Lampre-Merida has revealed that Diego Ulissi, winner of two stages at last month’s Giro d’Italia, has been notified by the UCI of an adverse analytical finding for an excessive amount of the anti-asthma drug salbutamol during the race. Both the rider and his team have questioned the amount of the substance found.
The 24-year-old from Tuscany, who won the fifth and eighth stages of the three-week race, was found to have 1900 ng/ml of salbutamol in his urine, nearly twice the maximum permitted level of 1000 ng/ml.
The Italian WorldTour team pointed out that prior to the samples being taken un the test at the end of Stage 11 in Savona, the rider followed correct procedures in notifying the testers of the medication he had taken that day.
In a statement, it said: “It is important to point out that Diego Ulissi, accompanied by Dr. Carlo Guardascione (head team doctor) had declared in his statement taken prior to the anti-doping control, the assumption before the race of Ventolin (2 puffs, equivalent to 100 ng of salbutamol each) and paracetamol during the race, the latter given by the race doctor due to the crash which occurred during the stage in which he had been involved with many other athletes.
Facebook
Twitter
Instagram